(CercleFinance.com) – Novo Nordisk announces the first results of a phase 3a trial comparing the effectiveness and safety of once-weekly IcoSema to insulin glargine U100 and insulin aspart (injected 2 to 4 times a day during meals) in 679 people with type 2 diabetes insufficiently controlled by daily basal insulin.
The trial met its primary endpoint of demonstrating non-inferiority of IcoSema in reducing HbA1c at week 52 compared to insulin glargine U100 and insulin aspart.
From an overall baseline HbA1c of 8.30%, once-weekly IcoSema achieved an estimated HbA1c reduction of -1.47 percentage points, compared to -1.40 percentage points for insulin glargine U100 and insulin aspart.
In the trial, IcoSema was superior to insulin glargine U100 and insulin aspart in estimated rates of severe or clinically significant hypoglycemia.
‘These results demonstrate the potential of IcoSema with only a single injection per week, compared to around 28 injections per week for people with type 2 diabetes insufficiently controlled by basal insulin,’ said Martin Holst Lange, vice-president. -executive president of development at Novo Nordisk.
Copyright (c) 2024 CercleFinance.com. All rights reserved.